WINDOW consortium: A path towards increased therapy efficacy against glioblastoma

Area of Science:

• Neuro-oncology
• Cancer therapy
• Translational research

Background:

• Glioblastoma is the most aggressive brain cancer with poor survival rates despite standard treatments.
• Tumor infiltration, chemotherapy resistance, and intratumoral heterogeneity complicate treatment efficacy.
• Existing therapies fail to halt glioblastoma progression due to these complex challenges.

Purpose of the Study:

• To establish a strategic approach for developing effective glioblastoma therapies.
• To address critical treatment barriers including drug resistance and tumor heterogeneity.
• To rationally select and develop novel therapeutic interventions for glioblastoma.

Main Methods:

• Overview of challenges in glioblastoma treatment.
• Discussion of strategies to overcome therapy resistance.
• Exploration of methods to improve blood-brain barrier penetration.
• Strategies to counter heterogeneous cell populations within tumors.

Main Results:

• Identified key challenges in glioblastoma treatment, including resistance and heterogeneity.
• Highlighted the need for orthogonal therapeutic approaches.
• Proposed a strategy for rational drug selection and development.
• Emphasized the importance of improved blood-brain barrier penetration.

Conclusions:

• A multi-faceted strategy is required to effectively treat glioblastoma.
• The WINDOW Consortium is developing a framework for novel glioblastoma therapies.
• Addressing intracellular resistance and intercellular heterogeneity is crucial for halting tumor progression.